May 22 (Reuters) - Biogen Inc ( BIIB ):

* BIOGEN BOLSTERS LATE-STAGE PIPELINE, EXPANDS IMMUNOLOGY

PORTFOLIO WITH AGREEMENT TO ACQUIRE HUMAN IMMUNOLOGY BIOSCIENCES

* BIOGEN INC ( BIIB ): BIOGEN WILL MAKE AN UPFRONT PAYMENT TO HI-BIO

OF

$1.15 BILLION.

* BIOGEN INC ( BIIB ): TRANSACTION TO INCLUDE FELZARTAMAB

* BIOGEN INC ( BIIB ): HI-BIO'S STOCKHOLDERS WOULD ALSO BE ELIGIBLE

FOR

PAYMENTS OF UP TO AN ADDITIONAL $650 MILLION

* BIOGEN INC ( BIIB ) - BIOGEN EXPECTS TO FINANCE ACQUISITION WITH

CASH AND

MAY ALSO DRAW ON ITS REVOLVING CREDIT AGREEMENT

* BIOGEN INC ( BIIB ): ACQUISITION OF HI-BIO IS NOT EXPECTED TO

IMPACT

BIOGEN'S PREVIOUSLY ISSUED 2024 GUIDANCE

Source text for Eikon:

Further company coverage: